+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID07223229

Randomized, Double-Blind Study Evaluating EI-001 Versus Placebo for Treating Non-segmental Vitiligo

Led by Elixiron Immunotherapeutics (Hong Kong) Ltd. · Updated on 2026-11-02

45

Participants Needed

8

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug EI-001 in adults with non-segmental vitiligo, a condition causing skin depigmentation. This Phase 2 study aims to assess whether EI-001, a novel antibody that modulates the immune system to reduce inflammation, can improve vitiligo symptoms. Previous studies showed EI-001 to be tolerable and a potential treatment for immune diseases, supporting its further investigation. Participants will receive either EI-001 or a placebo through infusion. EI-001 is supplied as a sterile solution with a protein concentration of 10.0 mgmL, while the placebo is a sterile sodium chloride solution. The study compares the effects of EI-001 against placebo in a randomized, double-blind design to evaluate its efficacy and safety over the treatment period. During the study, participants will undergo assessments including evaluation of vitiligo extent using the Facial Vitiligo Area Scoring Index F-VASI at baseline and Week 24. Researchers will monitor changes in vitiligo symptoms, treatment response rates, and any adverse events through Week 32. The study requires participants to discontinue other vitiligo treatments and complete vaccination against zoster if needed, with total participation lasting through the treatment and follow-up periods.

CONDITIONS

Brief Title

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here